Clinical Research Directory

Inclusion Criteria: * Patients with one of the high risk myeloid diseases as outlined below. Patients must have ≤ 5% blasts on the last BM evaluation prior to starting the conditioning regimen. Diseases included on this protocol include: 1. Acute Myeloid Leukemia (AML) in CR1 with intermediate or high risk features as defined below: °Cytogenetic abnormalities which are not considered "good risk" cytogenetic features (i.e t(8:21), t(15:17), inv 16 without c-kit mutations. And/or * Therapy related AML with history of antineoplastic therapy (radiation and/or chemotherapy) And/or * Normal karyotype with mutations of FLT3, RUNX1, TP53 mutation, ASXL1 or any others that are considered to be high risk 2. AML in ≥ 2nd remission 3. Myelodysplastic syndrome, myeloproliferative neoplasms, or MDS/MPN overlap syndrome with: °International prognostic scoring system risk score INT-2 or high risk at the time of transplant evaluation. And/or * Any risk category if life-threatening cytopenia exists And/or * Karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype. 4. Chronic myelomonocytic leukemia (CMML) 5. Chronic myeloid leukemia (CML) with the following features: °Patients who have failed or are intolerant to BCR-ABL tyrosine kinase inhibitors. And/or °CML with BCR-ABL mutation consistent with poor response to tyrosine kinase inhibition (e.g T351l mutation) 6. Patients with severe aplastic anemia * Chronic lymphocytic leukemia (CLL) with high risk disease as defined by the EBMT consensus criteria. * Non-Hodgkin lymphoma meeting both of the following criteria: * Responding to therapy prior to enrollment. * Relapse after prior autologous bone marrow transplant or are ineligible for autologous bone marrow transplant. * Multiple Myeloma with disease in the following categories: * Patients with relapsed multiple myeloma following autologous stem cell transplantation who have achieved at least partial response following additional chemotherapy * Patients with high risk cytogenetics at diagnosis must have achieved at least a partial response following autologous stem cell transplantation. Patients must have complex karyotype, del17p, t4;14, and/or t14;16 by FISH and/or del13 by karyotyping. * Each patient must be willing to participate as a research participant and must sign an informed consent form. * Organ Function and Performance Status Criteria: 1. Patients be ≥ 18 years old. 2. Patients must have a Karnofsky (adult) or Performance Status ≥ 70%. 3. Patients must have adequate organ function measured by: * Cardiac: asymptomatic or if symptomatic, then LVEF at rest must be ≥ 40% and must improve with exercise. * Hepatic: \< 5x ULN ALT and \< 2x ULN total serum bilirubin, unless there is congenital benign hyperbilirubinemia. * Renal: CrCl \>30ml/min (measured or calculated/estimated). * Pulmonary: asymptomatic or if symptomatic, DLCO \> 50% of predicted (corrected for hemoglobin) Exclusion Criteria: * Prior allogenic hematopoietic stem cell transplantation * Prior radiation therapy with 400cGY or more of TBI * BM with increased fibrosis (Reticulin stain \> 1/3) * Active and uncontrolled infection at time of transplantation * HIV infection * Seropositivity for HTLV-1 * Inadequate performance status/ organ function * Pregnancy or breast feeding * Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up, and research tests. Donor Inclusion and Exclusion Criteria: * Must be a 10/10 HLA genotypically match related or unrelated donor at all A, B, C, DRB1, and DQB1 loci, as tested by DNA analysis * Able to provide informed consent for the donation process per institutional standards * Meet standard criteria for donor collection as defined by the National Marrow Donor Program Guidelines